BR0011939A - Recursos e métodos para monitorar terapia anti-retroviral inibidora de protease e orientar decisões terapêuticas no tratamento de hiv/aids - Google Patents

Recursos e métodos para monitorar terapia anti-retroviral inibidora de protease e orientar decisões terapêuticas no tratamento de hiv/aids

Info

Publication number
BR0011939A
BR0011939A BR0011939-3A BR0011939A BR0011939A BR 0011939 A BR0011939 A BR 0011939A BR 0011939 A BR0011939 A BR 0011939A BR 0011939 A BR0011939 A BR 0011939A
Authority
BR
Brazil
Prior art keywords
hiv
treatment
aids
methods
resources
Prior art date
Application number
BR0011939-3A
Other languages
English (en)
Inventor
Neil T Parkin
Rainer A Ziermann
Original Assignee
Virologic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/591,899 external-priority patent/US6869759B1/en
Application filed by Virologic Inc filed Critical Virologic Inc
Publication of BR0011939A publication Critical patent/BR0011939A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS

Abstract

Patente de Invenção: "RECURSOS E MéTODOS PARA MONITORAR TERAPIA ANTI-RETROVIRAL INIBIDORA DE PROTEASE E ORIENTAR DECISõES TERAPêUTICAS NO TRATAMENTO DE HIV/AIDS". Esta invenção refere-se à suscetibilidade de droga antiviral e testes de resistência a serem empregados na identificação de regimes de drogas eficazes para o tratamento da infecção do vírus da imunodeficiência humana (HIV) e síndrome da imunodeficiência adquirida (AIDS), particularmente regimes de tratamento incluindo um inibidor de protease. A invenção também refere-se aos meios e métodos de monitorar a progressão clínica da infecção de HIV e sua resposta à terapia anti-retroviral empregando ensaios de suscetibilidade fenotípica e fenotípica.
BR0011939-3A 1999-06-22 2000-06-22 Recursos e métodos para monitorar terapia anti-retroviral inibidora de protease e orientar decisões terapêuticas no tratamento de hiv/aids BR0011939A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33832399A 1999-06-22 1999-06-22
US09/591,899 US6869759B1 (en) 1999-06-22 2000-06-12 Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
PCT/US2000/017178 WO2000078996A1 (en) 1999-06-22 2000-06-22 Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids

Publications (1)

Publication Number Publication Date
BR0011939A true BR0011939A (pt) 2002-03-12

Family

ID=26991134

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0011939-3A BR0011939A (pt) 1999-06-22 2000-06-22 Recursos e métodos para monitorar terapia anti-retroviral inibidora de protease e orientar decisões terapêuticas no tratamento de hiv/aids

Country Status (5)

Country Link
EP (1) EP1194587A4 (pt)
AU (1) AU5758200A (pt)
BR (1) BR0011939A (pt)
CA (1) CA2375905A1 (pt)
WO (1) WO2000078996A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1185712B8 (en) 1999-05-28 2005-10-19 Virco Bvba New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
US7186506B1 (en) 2000-06-12 2007-03-06 Monogram Biosciences, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US7138231B2 (en) * 2000-09-15 2006-11-21 Monogram Biosciences, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US6869759B1 (en) 1999-06-22 2005-03-22 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
AU2001260224A1 (en) 2000-04-18 2001-10-30 Virco Bvba Methods for measuring drug resistance
WO2002022076A2 (en) * 2000-09-15 2002-03-21 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
MXPA03003476A (es) 2000-10-20 2004-09-10 Virco Bvba Nuevos perfiles mutacionales en transcriptasa inversa de vih-1 correlacionan con resistencia fenotipica a farmaco.
EP1407042A4 (en) * 2001-06-04 2006-02-22 Virologic Inc METHOD AND METHOD FOR MONITORING ANTIRETROVIRAL PROTEASE INHIBITOR THERAPY AND AS A GUIDANCE FOR THERAPEUTIC DECISIONS IN THE TREATMENT OF HIV / AIDS
US7384734B2 (en) 2002-02-15 2008-06-10 Monogram Biosciences, Inc. Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
CA2491388A1 (en) 2002-07-01 2004-01-08 Virologic, Inc. Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
WO2004003223A2 (en) 2002-07-01 2004-01-08 Tibotec Pharmaceuticals Ltd. New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
EP1520247B1 (en) 2002-07-01 2009-05-27 Tibotec Pharmaceuticals Ltd. Mutational profiles in hiv-1 protease correlated with phenotypic drug resistance
DE60316807T2 (de) * 2002-07-01 2008-07-17 Tibotec Pharmaceuticals Ltd. Neue mutationsmuster in hiv-1 reverser transcriptase, die mit phenotypischer resistenz gegen medikamente korrelieren
CN1678755A (zh) 2002-07-01 2005-10-05 瓦罗洛吉克公司 确定致病性病毒对蛋白酶抑制剂易感性的组合物和方法
EP2162745A1 (en) 2007-05-25 2010-03-17 Tibotec Pharmaceuticals New mutational profile in hiv-1 gag cleavage site correlated with phenotypic drug resistance

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766842A (en) * 1994-09-16 1998-06-16 Sepracor, Inc. In vitro method for predicting the evolutionary response of a protein to a drug targeted thereagainst

Also Published As

Publication number Publication date
CA2375905A1 (en) 2000-12-28
EP1194587A4 (en) 2005-07-06
WO2000078996A1 (en) 2000-12-28
EP1194587A1 (en) 2002-04-10
AU5758200A (en) 2001-01-09
WO2000078996A9 (en) 2002-07-11

Similar Documents

Publication Publication Date Title
BR0011939A (pt) Recursos e métodos para monitorar terapia anti-retroviral inibidora de protease e orientar decisões terapêuticas no tratamento de hiv/aids
BR9912209A (pt) Recursos e métodos para monitoração de terapia anti-retroviral inibidora de transcriptase reversa de nucleosìdeo e guia de decisões terapêuticas no tratamento de hiv/aids
Imrie et al. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine
Safren et al. Quality of life among individuals with HIV starting antiretroviral therapy in diverse resource-limited areas of the world
CY1112172T1 (el) Φαρμακο για την αγωγη θηλαστικων μολυσμενων με hiv
BR9911600A (pt) Recursos e métodos para monitoração de terapia antiretroviral inibidora de transcriptase reversa de não nucleosìdeo
DK1026263T3 (da) Oligonukleotidprimere til omvendt transkription til effektiv detektering af HIV-1 og HIV-2 og fremgangsmåder til anvendelse deraf
ATE302287T1 (de) Neue mutationsprofile der hiv-1 reverse transcriptase in verbindung mit phänotypischem medikamentresistenz
Roca et al. Hepatitis C virus and human immunodeficiency virus coinfection in Spain
WO2002022076A3 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
Sood et al. Sofosbuvir–velpatasvir single-tablet regimen administered for 12 weeks in a phase 3 study with minimal monitoring in India
WO2002099387A3 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
BR0111575A (pt) Meios e métodos para monitorar a terapia anti-retroviral e orientar as decisões terapêuticas no tratamento de hiv/aids
Gutierrez et al. An outbreak of adenovirus type 8 keratoconjunctivitis in a nursing home in Madrid
Richman Clinical significance of drug resistance in human immunodeficiency virus
Stewart et al. An algorithm for mapping positively selected members of quasispecies-type viruses
Durier et al. Chronic hepatitis C infection and liver disease in HIV‐coinfected patients in Asia
WO2002022781A3 (en) Non-nucleoside reverse transcriptase inhibitor as antiretroviral therapy
MXPA03003476A (es) Nuevos perfiles mutacionales en transcriptasa inversa de vih-1 correlacionan con resistencia fenotipica a farmaco.
Peribañez-Gonzalez et al. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection
Ferré et al. Pharmaco‐virological algorithm to target risk of drug resistance among a population of HIV‐infected key populations in Togo
Price et al. Role of the psychiatrist in the care of patients with hepatitis C and HIV/AIDS
Manfredi et al. HIV-infected immigrants from non-European Union countries and antiretroviral treatment: comparison of epidemiologic, clinical, and therapeutic variables according to patient sex
Udeze et al. Hepatitis B and C seropositivity in a cohort of HIV-positive patients in Ilorin, North-central Nigeria
Langtry et al. Zidovudine: a review of pharmacoeconomic and quality-of-life considerations for its use in patients with human immunodeficiency virus

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 7O, 8O E 9O ANUIDADES.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.